|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 47/68 | (2017.01) |
| A61K 45/06 | (2013.01) | ||
| A61K 31/498 | (2006.01) | ||
| A61K 47/6849 | (2017.08) | ||
| A61K 47/6867 | (2017.08) | ||
| A61K 31/519 | (2006.01) | ||
| A61K 31/436 | (2013.01) | ||
| A61K 31/4745 | (2006.01) | ||
| A61K 31/5377 | (2006.01) | ||
| A61K 31/4375 | (2013.01) | ||
| A61K 31/4375 | (2006.01) | ||
| A61K 31/4745 | (2013.01) | ||
| A61K 31/436 | (2006.01) | ||
| A61K 31/498 | (2013.01) | ||
| A61K 45/06 | (2006.01) | ||
| A61K 31/519 | (2013.01) | ||
| A61P 35/00 | (2006.01) | ||
| A61K 31/5377 | (2013.01) | ||
| A61P 35/02 | (2006.01) | ||
| A61K 47/6811 | (2017.08) | ||
| A61P 35/00 | (2018.01) | ||
| A61P 35/02 | (2018.01) | ||
| A61P 43/00 | (2018.01) |
| (11) | Number of the document | 3581206 |
| (13) | Kind of document | T |
| (96) | European patent application number | 19173675.0 |
| Date of filing the European patent application | 2011-10-20 | |
| (97) | Date of publication of the European application | 2019-12-18 |
| (45) | Date of publication and mention of the grant of the patent | 2024-12-25 |
| (46) | Date of publication of the claims translation |
| (30) | Number | Date | Country code |
| 40576710 P | 2010-10-22 | US | |
| 201161445785 P | 2011-02-23 | US |
| (72) |
LEWIS, Timothy S. , US
LAW, Che-Leung , US
MCEARCHERN, Julie A. , US
|
| (73) |
Seagen Inc. ,
21823 30th Drive S.E., Bothell, WA 98021,
US
|
| (54) | SYNERGISTIC EFFECTS BETWEEN AURISTATIN-BASED ANTIBODY DRUG CONJUGATES AND INHIBITORS OF THE P13K-AKT MTOR PATHWAY |
| SYNERGISTIC EFFECTS BETWEEN AURISTATIN-BASED ANTIBODY DRUG CONJUGATES AND INHIBITORS OF THE PI3K-AKT MTOR PATHWAY |